To the Editor Using a microsimulation model, Dr Pandya and colleagues1 found that it was cost-effective to treat more than 60% of all US adults aged 40 through 75 years with a generic statin for primary prevention of atherosclerotic cardiovascular disease (ASCVD). Using a weighted average of the lowest Red Book wholesale acquisition costs for generic 20-mg tablets, the authors estimated costs of $11 per patient per year for simvastatin, $110 for atorvastatin, and $2277 for rosuvastatin in the base-case analysis.
Luo J, Kesselheim AS. Cost-effectiveness of Statin Therapy for ASCVD. JAMA. 2015;314(20):2191. doi:10.1001/jama.2015.12919